Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, small bowel resection extent, and prophylaxis treatment absence. Ileocolonoscopy within one year of surgery can predict clinical recurrence risk. Different therapies are proposed after surgery, to prevent post-operative recurrence : Thiopurines, 6-mercaptopurine (positive for clinical and endoscopic postoperative recurrence prevention), Anti-tumour necrosis factor therapy (anti-TNF), the most effective therapy. Intestinal microbiota acts as a central factor in the CD pathogenesis, and fecal stream role is clearly shown. Various changes in luminal flora with a possible link to local inflammation was also demonstrated. Bacteria associated with postoperative recurrence could be more pathogenic as adherent invasive E coli (AIEC), which could be a pathogen in CD through several mechanisms including increased mucosal colonization, adherence, replication and induction of TNF secretion. Alternatively, postoperative CD recurrence could be linked to a protective commensal species lack, such as Faecalibacterium prausnitzii. Microscopic inflammation occurs as early as 8 days after anastomosis in the neoterminal ileum mucosa. IL6, IL10 and TGFb levels, measured in neoterminal ileum early after surgery are associated with different rates of postoperative recurrence. It suggests cytokines implication in postoperative recurrence. T cells are major players in the intestinal immune response. The presence at time of surgery and persistence of disease inducing T cell clonal expansions could play an important role in post-operative recurrence. The main objective is to define a classification of ileal Crohn's Disease based on data integration on a large cohort of patients.

Who May Be Eligible (Plain English)

Who May Qualify: - willing to sign a consent form obtained before any study-related activities - A diagnosis of CD, based on clinical, radiologic, endoscopic, or histological evidence. - Men and women ≥18 years of age - Required surgical intervention consisting in an ileocecal resection Who Should NOT Join This Trial: - Previous history of dysplasia or cancer in the ileum or colon - Unwillingness or inability to follow the procedures outlined in the protocol - Pregnant women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Informed consent obtained before any study-related activities * A diagnosis of CD, based on clinical, radiologic, endoscopic, or histological evidence. * Men and women ≥18 years of age * Required surgical intervention consisting in an ileocecal resection Exclusion Criteria: * Previous history of dysplasia or cancer in the ileum or colon * Unwillingness or inability to follow the procedures outlined in the protocol * Pregnant women

Treatments Being Tested

OTHER

bio-banking collection

blood samples, biopsies, and surgical specimen collected in addition to usual practice

Locations (17)

SART Tilman Hospital
Liège, Belgium
Amiens Hospital
Amiens, France
Haut-levêque Hospital
Bordeaux, France
Clermont-Ferrand Hospital
Clermont-Ferrand, France
Beaujon Hospital
Clichy, France
Henri Mondor Hospital
Créteil, France
Kremlin-Bicêtre Hospital
Le Kremlin-Bicêtre, France
Lille Hospital
Lille, France
Hôpital Nord, CHU Marseille
Marseille, France
Montpellier Hospital
Montpellier, France
Brabois Hospital
Nancy, France
Nantes Hospital
Nantes, France
Archet 2 Hospital
Nice, France
Saint Louis Hospital
Paris, France
Saint Antoine Hospital
Paris, France
South Lyon Hospital
Pierre-Bénite, France
Strasbourg Hospital
Strasbourg, France